Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy.

(2017) E. Fumagalli et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy

(2015) M. Paez-Ribes et al.   CLINICAL CANCER RESEARCH

A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer

(2015) Laurence Albiges et al.   EUROPEAN UROLOGY

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases

(2015) Han-Sin Jeong et al.   JNCI-Journal of the National Cancer Institute

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases

(2015) Han-Sin Jeong et al.   JNCI-Journal of the National Cancer Institute

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

(2015) Terence C. Tang et al.   NEOPLASIA

Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma

(2015) Terence C. Tang et al.   NEOPLASIA

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design

(2014) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

(2014) M. Nowosielski et al.   NEUROLOGY

Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy

(2013) N S Vasudev et al.   BRITISH JOURNAL OF CANCER

Drug rechallenge and treatment beyond progression—implications for drug resistance

(2013) Elizabeth A. Kuczynski et al.   Nature Reviews Clinical Oncology

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

(2013) Krastan B. Blagoev et al.   Cell Reports

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

(2013) Tom Donnem et al.   Cancer Medicine

Sorafenib rechallenge in patients with metastatic renal cell carcinoma

(2012) Masahiro Nozawa et al.   BJU INTERNATIONAL

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth

(2012) Hannah van Malenstein et al.   CANCER LETTERS

Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step

(2012) Michael Herman Chui   INTERNATIONAL JOURNAL OF CANCER

Tumor budding in colorectal carcinoma: time to take notice

(2012) Bojana Mitrovic et al.   MODERN PATHOLOGY

Classifying collective cancer cell invasion

(2012) Peter Friedl et al.   NATURE CELL BIOLOGY

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

(2011) Wolfgang Wick et al.   Current Neurology and Neuroscience Reports

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression

(2011) Liang Zhang et al.   PLoS One

Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression

(2010) Rong-Xin Chen et al.   MOLECULAR BIOLOGY REPORTS

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT

(2009) Andrew Dennis Smith et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Sorafenib for Metastatic Renal Cancer

(2008) Rachel P. Riechelmann et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE